Elicit: Clinical Outcomes of TNF Inhibition in RA and Psoriasis
Clinical Outcomes of TNF Inhibition in RA and Psoriasis
Identify clinical evidence linking TNF inhibition to outcomes in rheumatoid arthritis and psoriasis
Abstract
TNF inhibitors demonstrate substantial therapeutic efficacy for psoriatic arthritis and psoriasis, with 37% of csDMARD-inadequate responders achieving clinical improvement (ACR50) versus 8% with placebo (RR 5.63, 95% CI 3.98 to 7.96). For moderate-to-severe plaque psoriasis, PASI 75 response rates reach 80-91% with infliximab compared to 3% with placebo, with therapeutic effects appearing within 4 weeks. However, paradoxical new-onset or worsening psoriasis emerges as a recognized adverse event in patients receiving TNF inhibitors for rheumatoid arthritis, occurring at 1.04 per 1000 person-years compared to 0 per 1000 person-years with traditional DMARDs. Adalimumab shows 4.6-fold higher incidence of paradoxical psoriasis than etanercept and 3.5-fold higher than infliximab, though no statistically significant differences in therapeutic effectiveness exist among anti-TNF agents. Most patients (66%) developing paradoxical psoriasis can continue TNF inhibitor therapy with concurrent psoriasis treatment.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Papers screened using criteria related to target population, intervention type, clinical outcomes, study design, population age, study type, sample size adequacy, and publication type.
Data extraction
Detailed extraction was performed on multiple aspects including study design, target conditions, patient population, TNF inhibitor details, primary outcomes, safety findings, key evidence, and study limitations.
Results
Characteristics of Included Studies
The review included 10 studies published between 2000 and 2025, comprising 5 randomized controlled trials, 3 meta-analyses/systematic reviews, 1 prospective registry study, and 1 retrospective cohort study. These studies addressed TNF inhibition in three distinct contexts: therapeutic use for psoriatic arthritis, therapeutic use for psoriasis, and paradoxical psoriasis development during TNF inhibitor therapy for other conditions.
| Study | Full text retrieved? | Study Type | Target Condition | TNF Inhibitor(s) | Sample Size | Primary Outcomes |
|---|---|---|---|---|---|---|
| L. Lemos et al., 2014 | No | Systematic review and meta-analysis | Psoriatic arthritis | Adalimumab, etanercept, golimumab, infliximab | Not mentioned | ACR20, ACR50, PsARC, PASI75 |
| G. Cagnotto et al., 2025 | No | Systematic review and meta-analysis of RCTs | Psoriatic arthritis | TNFi (specific agents not mentioned) | 7857 | ACR50, HAQ, SF-36 MCS, Sharp/Van der Heijde-PsA |
| E. Shmidt et al., 2012 | No | Retrospective cohort study | Psoriasis as adverse event | Infliximab, adalimumab, etanercept | 56 | Complete or partial response |
| Mark Harrison et al., 2008 | Yes | Prospective observational cohort (registry) | Rheumatoid arthritis; psoriasis as adverse event | Etanercept, infliximab, adalimumab | 9826 anti-TNF, 2880 DMARD | Incidence of new-onset psoriasis |
| Others | No |
Effects of TNF Inhibitors
Efficacy in Psoriatic Arthritis
TNF inhibitors demonstrated substantial clinical benefit in psoriatic arthritis. In csDMARD-inadequate responders, TNFi produced large improvements in clinical response at 12 weeks, with 37% achieving ACR50 compared to 8% with placebo (RR 5.63, 95% CI 3.98 to 7.96).
Efficacy in Psoriasis
TNF inhibitors exhibited high efficacy for moderate-to-severe plaque psoriasis. Infliximab showed the highest probability of PASI 75 achievement at 81%, followed by adalimumab at 71%.
Safety Profile
The safety profile of TNF inhibitors in psoriatic arthritis appeared favorable. At trial end, 4% of TNFi-treated patients experienced serious adverse events versus 3% with placebo.
Paradoxical Psoriasis During TNF Inhibitor Therapy
New-onset psoriasis emerged as a recognized adverse event among patients treated with TNF inhibitors, particularly when used for rheumatoid arthritis or inflammatory bowel disease. The crude incidence rate in a large cohort study was 1.04 per 1000 person-years in the anti-TNF cohort against 0 per 1000 person-years in the DMARD cohort.
Synthesis
The evidence reveals a paradox where TNF inhibitors demonstrate substantial efficacy in treating psoriatic arthritis and moderate-to-severe psoriasis while simultaneously inducing or exacerbating psoriasis in patients treated for other inflammatory conditions. The review emphasizes the importance of balancing efficacy in treatment with the management of paradoxical reactions.